Dopamine and Sensorimotor Function in Stuttering
ConditionStuttering, Adult
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of California, San Francisco
About this trial
This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.
Eligibility criteria
Qualifiers
native speakers of American English
for adults who stutter, presence of stuttering will be confirmed, with onset before age 6 years
Normal hearing
Ages of 18 to 65 years
Disqualifiers
self-reported speech-language-hearing difficulties other than stuttering
self-reported neurological or psychological problems
other medications (drugs that affect dopaminergic system and/or benzodiazepines)
Trial design
Treatments tested in this trial
- Aripiprazole 10 MG
- Placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, San Francisco
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator
University of Washington
Collaborator
Source ClinicalTrials.gov